- Home
- GVH vs ONCO Comparison
GVH vs ONCO Comparison
Compare GVH & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GVH | ONCO |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.3M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GVH | ONCO |
|---|---|---|
| Price | $1.23 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | ★ 177.6K | 137.4K |
| Earning Date | 01-30-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.95 | N/A |
| Revenue | ★ $21,878,867.00 | $1,223,751.00 |
| Revenue This Year | $141,706.20 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $0.10 | ★ N/A |
| Revenue Growth | ★ 24.52 | N/A |
| 52 Week Low | $1.09 | $1.31 |
| 52 Week High | $364.00 | $59.50 |
Technical Indicators
Market Signals| Indicator | GVH | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 35.26 |
| Support Level | $1.17 | $1.42 |
| Resistance Level | $1.29 | $2.30 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 34.21 | 8.08 |
Price Performance
Historical ComparisonAbout GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.